ArticleBMC cancer2025
Evolving treatments and outcomes in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a real-world study in China.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
backgroundThis single-centre retrospective study aimed to evaluate trends in the clinical characteristics, treatment approaches, and outcomes of patients with newly diagnosed multiple myeloma (NDMM) who underwent initial autologous stem cell transplantation (ASCT) between 2007 and 2023 in China.
methodsA total of 390 patients with NDMM were grouped into three time cohorts: 2007–2012 (79 patients), 2013–2018 (143 patients), and 2019–2023 (168 patients). Clinical characteristics, treatment regimens, and survival outcomes were analysed over these periods.
resultsThe results revealed increases in the proportions of patients older than 65 years, those with extramedullary disease (EMD), and those with secondary amyloidosis (systemic organ involvement by immunoglobulin light chain amyloid deposition with a diagnosis of MM). Treatment trends included the preference for bortezomib-based regimens, with the addition of daratumumab (Dara)-based therapies in the most recent cohort. The pre-ASCT MRD-negative rate increased from 8.5% in Cohort 1 to 29.8% in Cohort 3 (p = 0.001), with corresponding post-ASCT improvements in MRD-negative status (64.4% to 80.4%). Survival outcomes also improved, with the 5-year PFS rate increasing from 44.62% (Cohort 1) to 60.36% (Cohort 2) and 87.61% in the latest cohort (p < 0.001) and the 5-year OS rate increasing from 58.23% to 68.46% and 81.82% in the latest cohort (p = 0.011), respectively. High-risk cytogenetic abnormalities (HRCAs) were associated with poorer PFS and OS, although tandem ASCT for high-risk patients resulted in improved outcomes.
conclusionThis real-world study highlights substantial advancements in response depth and survival outcomes for patients with NDMM undergoing ASCT. These improvements were driven by the introduction of new drugs and refined risk stratification methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.